Stifel Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $30
Stifel analyst Laura Prendergast maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $48 to $30.
Stocks · News reference
Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures fell, with Nasdaq 100 futures down 500 points. Corning dropped 8% after a $2B offering; several other stocks also slid premarket.
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals announced the appointment of Jason V. O'Byrne as Chief Financial Officer effective August 11, 2026. As part of the appointment, O'Byrne received an employment inducement award of 650,000 stock options with an exercise price of $10.56 per share, vesting over four years with 25% vesting after one year and the remainder vesting monthly over three years.